The use of immune checkpoint inhibitor (ICI) therapy in the treatment of solid organ malignancies is becoming increasingly common. This has prompted the recognition of a new class of immune-related adverse effects (irAEs) stemming from the upregulation of T-cell activity causing autoimmunity. Neurological irAEs are a rare complication of ICIs that can lead to long-term morbidity. We report a rare case of encephalopathy after treatment with pembrolizumab, to which the patient achieved durable disease response despite discontinuation of therapy. We also review the pathophysiology, incidence, clinical presentation, diagnosis, and management of neurotoxicity secondary to ICIs. Treatment requires early administration of high-dose corticosteroids, and cessation of ICI therapy is often necessary after grade 3 or 4 irAEs. However, early data suggest that neurological irAEs correlate with a favorable disease response. Consideration should also be given to the optimal duration of ICI therapy to minimize the risk of toxicity and optimize health care expenditure.
Introduction
In recent times the clinical use of immune checkpoint inhibitors (ICIs) in a range of solid organ malignancies has become increasingly common. This has necessitated the recognition and documentation of a new class of treatment-related toxicities termed immune-related adverse effects (irAEs). It is well documented that such events are a consequence of upregulation of T-cell activity and can lead to a broad range of autoimmune sequelae causing clinical syndromes such as colitis, pneumonitis, and hepatitis. We report a case of encephalopathy caused by pembrolizumab and provide a comprehensive review of neurologic irAEs.
Case Study
In May 2013, a T1N0 right lower lobe NSCLC and solitary right frontal lobe cerebral metastasis were diagnosed in a 66-year-old man. His initial treatment included cerebral metastasectomy followed by whole brain radiotherapy (WBRT) in June 2013 and a right lower lobe lobectomy in September 2013. Histologic examination confirmed a large cell adenocarcinoma negative for EGFR and ALK receptor tyrosine kinase gene (ALK) mutations. His medical history included benign prostatic hypertrophy, dyslipidemia, gastroesophageal reflux, and hypertension. Concomitant medications included metoprolol, simvastatin, dutasteride/tamsulosin, and omeprazole.
After being disease-free for 2 years, he displayed evidence of progression on a positron emission tomography scan showing fludeoxyglucose F 18-avid disease within the mesentery and small bowel that was confirmed by biopsy. The patient was enrolled in the MK-3475 trial (Merck, Kenilworth, NJ) investigating the use of first-line pembrolizumab compared with standard chemotherapy (KEYNOTE-024 [ClinicalTrials.gov identifier NCT02142738]). He was randomized to the control arm and received carboplatin (dosed to an area under the concentration-time curve of 5.0 mg/mL/min) and pemetrexed, 500 mg/m 2 every 3 weeks for four cycles, followed by maintenance pemetrexed, 500 mg/m 2 every 3 weeks. After an initial response to treatment, computed tomography (CT) imaging showed evidence of progression after the patient had received two cycles of maintenance treatment and crossed over to pembrolizumab (200 mg intravenous administered intravenously every 3 weeks) in January 2016.
Four days after his second cycle of pembrolizumab, he was admitted with sudden onset of somnolence, confusion, ataxia, expressive dysphasia, and cognitive impairment. Formal testing of his higher functions revealed deficits in recall, orientation, fluency, subtraction, and attention. His Mini-Mental State Examination score was significantly reduced at 21/30.
Neurological examination revealed a glove and stocking distribution peripheral sensory neuropathy that was evident in both lower limbs to the knees, as well as loss of proprioception within the toes and ankle joints bilaterally, causing a compensatory broad-based gait. There was no evidence of meningism or cranial nerve deficits.
The results of routine blood tests, including a full blood count, biochemistry profile, thyroid function test, and measurement of C-reactive protein level, were within normal limits. The results of a vasculitic screen and testing for acetylcholine receptor antibodies were unremarkable. Lumbar puncture indicated normal opening pressures (14 cm H 2 O) and protein and glucose concentrations. His cerebrospinal fluid (CSF) was acellular with no growth on culture, and the results of polymerase chain reaction assay for John Cunningham virus on CSF were negative. Serum paraneoplastic antibodies (including anti-Hu, anti-Ri, anti-Yo, anti-Purkinje cytoplasmic antibody type 2, anti-amphiphysin, antiglutamic acid decarboxylase, and anti-Purkinje cell cytoplasmic antibody type Tr) and CSF anti-voltagegated potassium channel complex antibodies were not detected.
Brain CT was performed, ruling out obvious cerebral metastases or an ischemic event. Magnetic resonance imaging (MRI) of the brain showed a fluid-attenuated inversion recovery hyperintensity adjacent to the resection site, which is consistent with postoperative changes. An electroencephalogram (EEG) demonstrated generalized intermittent slowing consistent with a mild diffuse encephalopathy.
The overall clinical picture and EEG findings were most consistent with diffuse encephalopathy secondary to pembrolizumab. A cerebrovascular event, epilepsy, and encephalitis-particularly limbic encephalitiswere part of the initial differential diagnosis; however, the CSF, CT, MRI, and EEG findings alongside the clinical findings effectively ruled these out. The presentation was thought unlikely attributable to the effects of previous WBRT because of the acute onset and temporal association with the administration of pembrolizumab. As is standard practice for the treatment of severe irAEs, the patient was given high-dose methylprednisolone administered intravenously at 1 g daily for 3 days. His symptoms improved markedly after 3 days, with nearcomplete resolution of his expressive dysphasia and improvement in gait. The patient was discharged on a regimen of 60 mg of prednisolone daily, which was subsequently weaned by 10 mg each week. At last review in May 2017, the improvement in neurological function has been maintained. Furthermore, a recent EEG demonstrated that the encephalopathic changes found during the acute event have now completely resolved.
Although pembrolizumab was permanently discontinued after only two doses, the most recent restaging scans more than a year after cessation of treatment show maintenance of response in the mesenteric and small bowel disease ( Figure 1 ).
Discussion
ICIs are now routinely used in clinical practice. They have proven efficacy in a wide range of tumor types, including melanoma, 1 renal cell carcinoma 2 , urothelial carcinoma, 3 and NSCLC. 4, 5 As a group, their mechanism of action involves the inhibition of down-regulatory signals directed toward T cells. The two most effective checkpoint targets are cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), and the programmed cell death-1 receptor and ligand (PD-1/programmed death ligand 1). Inhibition of these physiologic checkpoints cause upregulation of cytotoxic T-cell activity and tumor death. 6, 7 To date, a range of ICIs have been manufactured, including but not limited to nivolumab and pembrolizumab (PD-1 inhibitors), ipilimumab (a CTLA4 inhibitor), and durvalumab and atezolizumab (programmed death ligand 1 inhibitors).
Occasionally, the upregulation of T-cell activity leads to disruption of immune tolerance, ultimately causing autoimmune syndromes in a variety of host tissues. Although the rates of irAEs are lower with PD-1 inhibitors than with CTLA4 inhibitors, 8 toxicities are not uncommon and can be severe. The rates of irAEs of any grade in a phase III trial of pembrolizumab were as follows: fatigue, 20%; diarrhea, 14%; rash; 13%; hypothyroidism, 8%; hyperthyroidism, 3%; and hepatitis, 1.8%. 1 Neurological adverse events are rare but have been documented with ICI therapy (Table 1 9-26 ). Although most are responsive to corticosteroid therapy, many are associated with long-term disability, making the prompt identification and treatment of these irAEs paramount when using ICIs.
Pathophysiology
The exact pathophysiology leading to irAEs remains unclear. There appear to be several different mechanisms involved in the development of irAEs rather than a singular process. Many irAEs manifest similarly in response to autoimmune diseases, suggesting that they share mechanisms leading to failure in selftolerance. Polymorphisms in CTLA4 have been associated with Grave's disease, Hashimoto's thyroiditis, diabetes, celiac disease, and myasthenia gravis. Systemic lupus erythematosus and rheumatoid arthritis can arise from single-nucleotide polymorphisms in PD-1 expression. 8 In some cases, shared antigens expressed on both tumor and host tissue lead to damage of healthy tissue. Quirk et al. demonstrated that ipilimumab-induced rash in melanoma is due to the development of intolerance to the melanin-A protein which is expressed on both melanoma cells and melanocytes. 27 Both PD-1 and CTLA4 inhibition have been shown to stimulate antibody production, leading to antibody-mediated autoimmune diseases. Kawamoto et al. demonstrated that PD-1 deficiency leads to an imbalance on T follicular helper cells within Peyer's patches, alteration of IgA secretion, and subsequent gut microbiota. 28 Another study, in which colonic biopsies were performed before and after the administration of ipilimumab, and showed that in patients in whom colitis developed, there was a dysregulation in antibody titers against enteric flora, causing lymphocyte infiltration and inflammation. 29 Even less is known regarding the pathogenesis specifically related to neurological irAEs. Checkpoint inhibition can precipitate underlying autoimmune disorders. For example, ipilimumab can induce and exacerbate myasthenia gravis, a disease caused by T-cellmediated production of acetylcholine receptor antibodies. 30 Paraneoplastic syndromes may provide a clue as to which shared neuron-specific antigens may precipitate autoimmunity and irAEs. In a phase II trial, antineuronal antibodies such as anti-SRY-box 2 (SOX2), anti-Hu, and anti-Yo (implicated in paraneoplastic syndromes causing cerebellar degeneration, encephalomyelitis and subacute sensory neuropathy) were detectable in 45% of patients with SCLC treated with ipilimumab and chemotherapy. Development of irAEs was more likely in those with positive autoantibody titers, but they also had a significantly longer median progression-free survival. 31 Furthermore, small vessel vasculitis has been implicated in a case of multifocal polyneuropathy, with nerve biopsy showing endoneural perivascular inflammatory infiltrate without Wallerian degeneration or demyelination. 32 In a case of transverse myelitis, biopsy of the cord lesion demonstrated necrotizing myelopathy with lymphocyte infiltration. 33 Cytokine production also appears to have a role in immune-mediated neurological damage. Increased levels of interleukin-6 have been demonstrated in some patients after treatment with ipilimumab, 34 which has been associated with demyelinating and inflammatory neurological conditions such as multiple sclerosis and transverse myelitis. 35 
Incidence
The incidence of neurological irAEs is poorly defined and often not well reported in phase III clinical trials. A recent literature review found the overall rate of any grade neurological irAEs to be 3.8% with anti-CTLA4 antibodies, 6.1% for anti-PD-1 therapy, and 12.0% for the combination thereof. 36 However, the incidence of grade 3 and 4 irAEs was less than 1% across all ICIs. A comprehensive review of patients at the Royal Marsden Hospital who received ICI therapy found a neurotoxicity rate of 2.4%. 37 Another multicenter review found a 3.2% incidence of neurological side effects in a population of patients with melanoma who received a PD-1 inhibitor. 38 The EORTC 18071 trial was one of the few phase III trials reporting neurological irAEs, at a rate of 4% in the adjuvant ipilimumab arm. 39 
Risk Factors
It is difficult to predict those patients in whom development of neurological irAEs is more likely. Consistent with other irAEs, the combination of PD-1 and CTLA-4 inhibition appears to increase the incidence of neurological toxicity. A single-center review found that the rate of neurological irAEs increased from 2.4% to 14% in patients who received a combination of ipilimumab and nivolumab. 37 ICIs can precipitate a flare of preexisting autoimmune disease, with several studies showing a 27% to 42% risk for mild to moderate exacerbation of the underlying autoimmune disorder with no increase in risk for development conventional irAEs. 40, 41 In case reports, ipilimumab appears to be more commonly associated with neurological irAEs than with PD-1 inhibitors 18 ; however, PD-1 inhibitors may confer a greater risk over time because of their prolonged duration of administration. 37 
Presentation and Diagnosis
Neurological irAEs can involve both the central and peripheral nervous system. Presentations range from nonspecific symptoms, such as fatigue, headache, vertigo, paraesthesia, and dysgeusia, to clinical syndromes, such myasthenia gravis, 21 Guillain-Barré syndrome, 24 chronic inflammatory demyelinating polyneuropathy, transverse myelitis, meningitis, 19 limbic encephalitis, 9 and posterior reversible encephalopathy syndrome. 18 The entity of peripheral neuropathy (which includes focal and peripheral neuropathies, Gullain-Barré-like syndromes, and meningoradiculitis) predominates in case reports in the literature. 36 More than 10 cases of encephalitis have been published in the literature. The most frequent presenting complaints have been cognitive impairment, memory loss, and gait disturbance. In a case presented by Salam et al. 9 subacute memory loss developed in a patient without other neurological deficits after 12 months of pembrolizumab. Brain MRI revealed T2 signal change within the hippocampi and anterior temporal lobe and insula, and analysis of CSF showed proteinemia and lymphocytosis. The results of EEG and a paraneoplastic antibody panel were normal. Despite treatment with methylprednisolone administered intravenously, no neurological improvement was seen. In another patient, encephalopathy developed 12 months after administration of ipilimumab. Similarly to in our case, EEG showed generalized slowing. The level of protein in the CSF was mildly increased; however, the brain MRI and paraneoplastic antibody panel findings were normal. The patient received 1000 mg of methylprednisolone administered intravenously for 3 days followed by a slow prednisolone wean. In this case, the neurological symptoms improved over the course of several months. 16 As with other irAEs, onset can occur at any point during ICI administration. However, most presentations seem to occur early on, with several case series reporting 60% to 80% of neurological irAEs developing within 4 months of the start of immunotherapy. 33, 37, 38 Diagnosis of neurological irAEs can be difficult because of the diverse range of signs and symptoms. In addition to this, clinical presentations often have atypical features, and despite a hypothesized autoimmune mechanism, no reliable markers or autoantibodies have been identified. 36 Patients can present with a mixture of upper and lower motor neuron signs or with a collection of neurological symptoms that do not fit a particular diagnosis. Our patient presented not only with encephalopathy and EEG changes but also with a confounding peripheral sensory neuropathy. Consequently, prompt diagnosis of neurological irAEs requires clinical vigilance. Any patient receiving treatment with ICIs should be educated and specifically documented acknowledging possible neurological irAEs. New neurological symptoms, even if atypical, should be monitored closely and investigated in consultation with a neurologist. 33 A range of diagnostic tools should be used. A detailed neurologic examination is paramount to document the trajectory of illness and response to treatment. Modalities such as brain MRI, lumbar puncture, and nerve conduction studies should be readily requested if available to aid in rapid diagnosis. CSF leukocytosis or proteinemia with oligoclonal bands is often seen in inflammatory or demyelinating conditions. 21, 24 Sensory and motor neuropathies often yield abnormal nerve conduction study results, 24 and T2 or fluid-attenuated inversion recovery changes on MRI and EEG changes may be seen in encephalopathy. 9 The results of testing for classic autoimmune and paraneoplastic antibodies in CSF and serum are usually negative, although there has been one case report of encephalitis with positive anti-N-methyl-D-aspartate antibodies. 20 Patients who present with myasthenia gravis will most likely have a positive acetylcholine receptor antibody test and show fatigability on repetitive nerve stimulation testing. 36 The diagnosis of neurological irAEs should be made after exclusion of other routine causes such as infection, space-occupying lesions, toxins, and metabolic and autoimmune disorders. Treatment with high-dose steroids should be initiated promptly even if not all the symptoms and signs fall under one diagnostic umbrella.
In our case study, the diagnosis of encephalopathy was made on the basis of EEG and clinical findings. The onset of illness had a temporal correlation with the commencement of pembrolizumab, and thus high-dose corticosteroid was swiftly commenced. The symptoms demonstrated response after the administration of methylprednisolone intravenously. Atypical features of the case were the absence of objective signs of encephalitis such as CSF lymphocytosis or signal changes on brain MRI scans. The extent to which the patient's prior exposure to WBRT affected his risk for development of encephalopathy is unclear. There are limited data examining the use of immunotherapy in patients with prior WBRT. Ionizing radiation is thought to enhance the immune response through increasing the major histocompatibility complex class I expression of tumor antigens. Preliminary studies looking at combining immunotherapy and radiotherapy in extracranial disease show a synergistic effect, with improved duration of response and no increase in irAEs. 42 Conversely, case reports of brain necrosis after stereotactic radiation and ipilimumab have been published 43 ; however, further studies are required to define the combined effect of radiotherapy and immunotherapy to the brain. response rate (ORR) of 70% in patients in whom neurological irAEs developed (in contrast to a 20%-30% ORR in phase III trials), with a median overall survival of 45.7 months compared with 11.2 months in those without neurological irAEs. 37 Data from both Zimmer et al. 38 and Blackmon et al. 33 reveal that 50% of patients with neurological irAEs achieved a partial or complete response. A recent case series reported a 90% ORR in 40 patients in whom neurological irAEs developed. 45 Although conclusions cannot be drawn from anecdotal and uncontrolled data, there is a suggestion that the development of neurological irAEs may be associated with an increase in ORR. At the very least, use of the high-dose corticosteroids required to treat neurological irAEs does not attenuate the efficacy of ICIs.
Despite the required discontinuation of therapy after only two doses, our patient had a sustained response on imaging more than 12 months later. These findings indicate that the effect of ICIs may be more akin to vaccine therapy than to targeted therapy. The current guidelines recommend that ICIs be continued until disease progression or unacceptable toxicity, although many clinical trials accept discontinuation if complete response is achieved after a prespecified time frame. However, the durable response seen in our patient after only two doses questions whether the duration of immunotherapy can be shortened once the immune system is appropriately primed.
Further trials are needed to elucidate the optimal duration of immunotherapy and the relationship between the development of irAEs and response rates. Shortening the duration of ICI therapy will have a significant impact on the economic burden with this class of drug and may also reduce the risk for irAEs.
Conclusion
Neurological irAEs will become more prevalent with the increasing use of ICI therapy. The wide variety of clinical presentations can make diagnosis challenging, and clinical vigilance is required in patients who are receiving ICIs and present with new neurological symptoms. Further research is required to explore the underlying mechanisms, treatment, and prevention of neurological irAEs. Given that many case series demonstrate higher ORR and durable responses despite discontinuation of ICIs, further efforts need to be made to clarify the optimal duration of treatment to minimize toxicity from long periods of exposure and optimize health care expenditure.
